AstraZeneca

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. It is dedicated to pushing the boundaries of science to deliver life-changing medicines to patients.

CCI Score

-12.13

0.01% April 18

Latest Event

AstraZeneca's 2023 Lobbying Expenditure

AstraZeneca spent $4,630,000 on federal lobbying in 2023 as reported by OpenSecrets. The expenditure raises concerns over potential corporate influence on policy-making in ways that may undermine democratic accountability.

Take Action

So what can you do? It's time to make tough choices. Where will you cast your vote?

Shop Alternatives SEE ALL: Argenx

Almirall

Verona Pharma
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

ENABLER

AstraZeneca is currently rated as an Enabler.

-10 to -19 CCI Score

Companies in this segment facilitate authoritarian practices while claiming neutrality. They provide resources or support that indirectly bolster oppressive regimes, thereby undermining democratic accountability without overtly endorsing the regime.

Latest Events

DEC

31

2023

AstraZeneca's 2023 Lobbying Expenditure
-61.47

AstraZeneca spent $4,630,000 on federal lobbying in 2023 as reported by OpenSecrets. The expenditure raises concerns over potential corporate influence on policy-making in ways that may undermine democratic accountability.
-70

Political Contributions and Lobbying Efforts

April 1

AstraZeneca’s allocation of $4.63M for lobbying activities in 2023 suggests a significant investment in influencing federal policy. Such spending is interpreted as leveraging corporate power to shape regulatory environments in favor of business interests, potentially at the expense of public accountability and worker rights. This action aligns with practices that may indirectly support authoritarian dynamics.

AstraZeneca PLC Lobbying Profile – OpenSecrets
NOV

08

2023

AstraZeneca Upgrades Campus Security with New Surveillance System
17.31

AstraZeneca announced a partnership with Axis Communications to deploy advanced surveillance technology at its Gaithersburg R&D campus. The upgrade aims to bolster campus security, improve lab safety, enhance operational efficiency, and support emergency preparedness through state‑of‑the‑art video management systems and analytical tools.
+20

Business Practices and Ethical Responsibility

April 1

The upgrade of surveillance and security systems is positioned as an improvement in employee safety and operational processes at the Gaithersburg campus. Enhanced safety measures contribute to a better work environment and align with responsible business practices, which is viewed positively under ethical responsibility.

AstraZeneca partners with Axis Communications
+20

Technology and Services Impact

April 1

The deployment of advanced surveillance technology, including features like high-speed PTZ cameras and analytical tools, modernizes the company’s operational infrastructure. While surveillance tech can raise concerns in different contexts, here it is implemented to enhance campus security and support efficiency, yielding a moderate positive impact under technology and services.

AstraZeneca partners with Axis Communications
NOV

03

2023

AstraZeneca Implements Enhanced Surveillance Solutions
-25.93

AstraZeneca has deployed a new surveillance system at its Gaithersburg R&D center in partnership with Axis Communications. The advanced system, featuring multisensor cameras, analytics, and integrated access control, is designed to improve safety, space planning, and emergency response. However, the widespread use of such surveillance technology raises concerns about normalizing pervasive monitoring that could potentially extend beyond operational efficiency into areas of worker privacy and control.
-30

Provision of Repressive Technologies

April 1

Although the surveillance upgrade is touted for enhancing safety and operational efficiency at AstraZeneca’s Gaithersburg facility, the deployment of advanced multisensor cameras and analytics can contribute to the normalization of extensive surveillance measures. This practice, if expanded or misused, may enable invasive monitoring of employees and support authoritarian management tendencies, raising red flags from an anti-fascist perspective.

AstraZeneca enhances security with surveillance solutions
NOV

01

2023

AstraZeneca Upgrades Campus Security with Axis Partnership
21.59

AstraZeneca’s Gaithersburg R&D center in Maryland has partnered with Axis Communications to deploy an advanced surveillance system that enhances campus security, lab safety, operational efficiency, and emergency preparedness.
+30

Technology and Services Impact

April 1

The integration of AXIS Camera Station and advanced analytics improves safety measures and operational efficiency at AstraZeneca’s R&D center. While surveillance technology can be a double‐edged sword, in this instance it is implemented to enhance emergency response, space planning, and lab safety, supporting a progressive agenda for worker and community protection.

AstraZeneca Partners With Axis Communications to Improve Security and Enhance Operational Efficiency at Maryland R&D Facility
+20

Business Practices and Ethical Responsibility

April 1

Upgrading the surveillance system not only bolsters security but also contributes to safer working conditions for approximately 3,500 employees, thus furthering ethical business practices by prioritizing employee safety and operational integrity.

AstraZeneca Partners With Axis Communications to Improve Security and Enhance Operational Efficiency at Maryland R&D Facility